Seventure Partners is a Paris-based venture capital firm established in 1997, specializing in investments in life sciences and digital technology sectors. With a strong presence in Europe and additional offices in Munich, Geneva, London, and Basel, the firm manages approximately €660 million as of late 2016. Seventure Partners focuses on supporting innovative companies that demonstrate significant growth potential, investing primarily in North America, Europe, Asia-Pacific, the Middle East, and Africa. The firm engages actively with entrepreneurs, providing them with valuable expertise, networks, and resources to accelerate their development. Seventure's investment strategy typically involves funding ranges from €0.5 million to €2 million, aiming to foster the emergence of future European leaders in technology and healthcare. With a team of over 20 professionals, including around 15 investors, Seventure Partners leverages its deep industry knowledge to navigate the venture capital landscape effectively.
BCD Bioscience, Inc. designs and develops an oligosaccharide library and a roadmap that connects precise carbohydrate structures with their functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. It offers a platform for creating and commercializing novel prebiotics, synbiotics, and immuno- modularity therapies for human and animal health. BCD Bioscience, Inc. was formerly known as Calyxo Biosystems, Inc. and changed its name to BCD Bioscience, Inc. in November 2019. The company was incorporated in 2019 and is based in Davis, California.
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.
PROTEON uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. We have developed a platform to develop and deliver bacteriophages for animal health solutions. Our pipeline includes solutions to prophylactically improve performance and food safety in poultry, as well as important prevent economically important bacterial diseases in aquaculture and dairy.
CytoKi Pharma ApS, a discovery stage biotech company, develops treatments for epithelial injury based diseases with an unmet medical need. The company was founded in 2019 and is based in Værløse, Denmark.
Iome Bio is a French company founded on discoveries from Sharpe and Kasper (Harvard) laboratories that explore microbiome-based mechanisms to develop new drugs in immuno-oncology. In particular, the company is working on new targets to overcome resistance to checkpoint inhibitors.
Animab BV, a biotechnology company, develops monoclonal antibodies for livestock. It develops mimic secretory IgA, a type of natural antibody passed through colostrum and milk to protect nursing animals. The company will help swine producers with antibiotics for the control of gastrointestinal pathogens. Animab BV was incorporated in 2020 and is based in Ghent, Belgium.
Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company's microbial therapy leverages naturally occurring or engineered bacteria along with a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses. This approach has potential in a wide range of human conditions, from metabolic disorders and cholestatic diseases to cancer and autoimmune conditions.
Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
ViroVet NV develops virus control solutions for the livestock industry. It offers antiviral drugs for the control and treatment of respiratory diseases of cattle and swine. The company also offers modified live virus vaccines for endemic and epizootic viral livestock diseases. ViroVet NV was founded in 2015 and is based in Leuven, Belgium.
BCD Bioscience, Inc. designs and develops an oligosaccharide library and a roadmap that connects precise carbohydrate structures with their functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. It offers a platform for creating and commercializing novel prebiotics, synbiotics, and immuno- modularity therapies for human and animal health. BCD Bioscience, Inc. was formerly known as Calyxo Biosystems, Inc. and changed its name to BCD Bioscience, Inc. in November 2019. The company was incorporated in 2019 and is based in Davis, California.
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.
Novobind Livestock Therapeutics Inc. is an integrated animal health company based in Vancouver, Canada, focused on developing next-generation biologics to combat pathogens that significantly impact livestock, aquaculture, and pets. Founded in 2012, the company addresses the challenges of rising resistance to anti-infectives and the accumulation of harmful residues in the environment. By targeting specific bacteria, viruses, and parasites responsible for intestinal ailments, Novobind aims to reduce production losses exceeding $1 billion and improve food safety for producers. Through its innovative approach, the company supports the animal sector in minimizing waste and enhancing health outcomes for various animal populations.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.
LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering the intestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that serve as a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, focusing particularly on transcriptomics. By enabling single-cell barcoding in a test tube format, Scipio Bioscience's products facilitate advanced research in single-cell analysis, supporting laboratories in their scientific endeavors.
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in developing Eligobiotics, a novel class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, Eligo Bioscience utilizes a combination of the CRISPR/Cas system and engineered phage capsids to create antibiotics aimed at treating diseases associated with the human microbiome and resistant pathogens. Their innovative approach allows for the precise eradication of virulent bacteria, addressing the growing challenge of antibiotic resistance. The potential applications of their technology extend beyond therapeutics to include areas such as cosmetics and biodefense, positioning Eligo Bioscience at the forefront of next-generation antimicrobial development.
Anaeropharma Science, Inc. is a biopharmaceutical company based in Chiyoda, Japan, founded in 2004. The company specializes in the development of therapeutics aimed at treating solid cancers characterized by hypoxic environments. Utilizing its proprietary platform technology, which involves recombinant Bifidobacterium, Anaeropharma Science develops innovative solutions including APS001F for solid tumors, anticancer drugs in the immuno-oncology sector, and treatments for ischemia such as FGF2. The company's approach leverages genetically enhanced bacteria that thrive in the low-oxygen conditions typical of solid tumors, where they convert systemically administered pro-drugs into cytotoxic agents, thereby providing healthcare professionals with effective and safe therapeutic options for cancer and related hypoxic conditions.
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in developing Eligobiotics, a novel class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, Eligo Bioscience utilizes a combination of the CRISPR/Cas system and engineered phage capsids to create antibiotics aimed at treating diseases associated with the human microbiome and resistant pathogens. Their innovative approach allows for the precise eradication of virulent bacteria, addressing the growing challenge of antibiotic resistance. The potential applications of their technology extend beyond therapeutics to include areas such as cosmetics and biodefense, positioning Eligo Bioscience at the forefront of next-generation antimicrobial development.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.
Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options.
To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.
Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.
Genome Express
Series B in 2001
Genome Express SA operates as a biotechnology company. It provides DNA synthesis, DNA sequencing, and DNA libraries to pharmaceutical, agro-food companies, and academic laboratories. The company develops and markets value-added solutions in functional and exploratory genomics and functional proteomics for discovery processes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.